Neuropeptide Y Protects Retinal Nerve Cells in a Mouse Model of Glaucoma
Injecting neuropeptide Y into the eyes of mice with glaucoma preserved retinal nerve cells, reduced inflammation, and prevented optic nerve damage through multiple protective pathways.
Quick Facts
What This Study Found
Neuropeptide Y (NPY) treatment preserved both structural and functional integrity of the inner retina in a mouse model of glaucoma with elevated intraocular pressure. NPY mitigated axonal damage and optic nerve degeneration, reduced inflammatory glial cell activation (decreased GFAP and Iba-1 expression), and restored endogenous NPY and receptor levels (NPY-Y1R and NPY-Y4R) that were depleted under high pressure conditions.
Molecular analysis revealed NPY works through MAPK and PI3K/Akt signaling pathways to achieve its protective effects.
Key Numbers
36-amino-acid peptide · NPY-Y1R and NPY-Y4R receptors restored · GFAP and Iba-1 reduced · MAPK and PI3K/Akt pathways activated
How They Did This
Mouse glaucoma model using intracameral microbead injections to elevate intraocular pressure, combined with intravitreal injection of NPY peptide. Researchers assessed retinal structure and function, optic nerve integrity, inflammatory markers (GFAP, Iba-1), endogenous NPY and receptor expression, and molecular signaling pathways (MAPK, PI3K/Akt).
Why This Research Matters
Glaucoma is a leading cause of irreversible blindness, and current treatments focus on lowering eye pressure without directly protecting the nerve cells that die. This study shows a natural brain peptide — neuropeptide Y — can directly protect retinal ganglion cells from pressure-induced damage through multiple mechanisms: reducing inflammation, preventing cell death, and restoring healthy signaling. It opens a potential new therapeutic avenue that targets the neurodegeneration itself, not just the pressure.
The Bigger Picture
Current glaucoma treatments focus almost exclusively on lowering intraocular pressure, but many patients continue to lose vision despite controlled pressure. Neuroprotective approaches that directly shield retinal ganglion cells represent the next frontier. NPY's ability to work through multiple mechanisms — anti-inflammatory, anti-apoptotic, and neurotrophic — makes it a particularly promising candidate in a field that desperately needs alternatives.
What This Study Doesn't Tell Us
This is a mouse model study — results may not directly translate to human glaucoma. Intravitreal injection is invasive and would need practical delivery solutions for clinical use. The study does not report long-term outcomes or whether repeated dosing would be needed. Specific quantitative outcomes (e.g., percentage of ganglion cell preservation) are not detailed in the abstract.
Questions This Raises
- ?Could NPY be delivered to the eye through less invasive methods like eye drops or sustained-release implants?
- ?Would NPY treatment also benefit patients whose glaucoma progresses despite normal eye pressure (normal-tension glaucoma)?
- ?How long does the protective effect of a single NPY injection last in the retina?
Trust & Context
- Key Stat:
- Preserved inner retinal integrity under high IOP NPY treatment maintained both structure and function of retinal ganglion cells that would otherwise degenerate from elevated eye pressure
- Evidence Grade:
- Rated moderate because this is a well-designed animal study published in a reputable journal (PNAS Nexus) with clear mechanistic data, but has not yet been tested in humans.
- Study Age:
- Published in 2024, this is a recent addition to the growing body of evidence for neuropeptide-based neuroprotection in eye disease.
- Original Title:
- Neuropeptide Y receptor activation preserves inner retinal integrity through PI3K/Akt signaling in a glaucoma mouse model.
- Published In:
- PNAS nexus, 3(8), pgae299 (2024)
- Authors:
- Palanivel, Viswanthram(3), Gupta, Vivek(3), Chitranshi, Nitin(3), Tietz, Ole, Vander Wall, Roshana, Blades, Reuben, Maha Thananthirige, Kanishka Pushpitha, Salkar, Akanksha, Shen, Chao, Mirzaei, Mehdi, Gupta, Veer, Graham, Stuart L, Basavarajappa, Devaraj
- Database ID:
- RPEP-09013
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What is neuropeptide Y and where is it normally found?
Neuropeptide Y is a 36-amino-acid peptide naturally produced in the brain and nervous system. It plays roles in appetite, stress response, and nerve cell survival. This study found it's also present in the retina, where its levels drop during glaucoma.
Could this lead to a new glaucoma treatment?
Potentially, but it's early. This mouse study proves the concept works in animals and identifies the biological pathways involved. Human clinical trials would need to confirm safety and efficacy before NPY could become a glaucoma treatment, which typically takes many years.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09013APA
Palanivel, Viswanthram; Gupta, Vivek; Chitranshi, Nitin; Tietz, Ole; Vander Wall, Roshana; Blades, Reuben; Maha Thananthirige, Kanishka Pushpitha; Salkar, Akanksha; Shen, Chao; Mirzaei, Mehdi; Gupta, Veer; Graham, Stuart L; Basavarajappa, Devaraj. (2024). Neuropeptide Y receptor activation preserves inner retinal integrity through PI3K/Akt signaling in a glaucoma mouse model.. PNAS nexus, 3(8), pgae299. https://doi.org/10.1093/pnasnexus/pgae299
MLA
Palanivel, Viswanthram, et al. "Neuropeptide Y receptor activation preserves inner retinal integrity through PI3K/Akt signaling in a glaucoma mouse model.." PNAS nexus, 2024. https://doi.org/10.1093/pnasnexus/pgae299
RethinkPeptides
RethinkPeptides Research Database. "Neuropeptide Y receptor activation preserves inner retinal i..." RPEP-09013. Retrieved from https://rethinkpeptides.com/research/palanivel-2024-neuropeptide-y-receptor-activation
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.